Contact
searchSearch
HMP Global
Login

Chronic Myeloid Leukemia Excellence Forum

Chronic Myeloid Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

David Andorsky, MD
Conference Coverage
Novel Allosteric BCR::ABL1 Inhibitor TERN-701 Demonstrates Encouraging Efficacy for Chronic Myeloid Leukemia: CARDINAL Study
01/05/2026
David Andorsky, MD
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented...
01/05/2026
Oncology
Jorge Cortes, MD
Videos
Latest Advancements in the Treatment of Chronic Myeloid Leukemia
09/10/2025
Jorge Cortes, MD
Jorge Cortes, MD shares recent progress in the treatment of chronic myeloid leukemia, highlighting the use of asciminib for patients including those who have not responded to other tyrosine kinase inhibitors.
Jorge Cortes, MD shares recent progress in the treatment of chronic myeloid leukemia, highlighting the use of asciminib for patients including those who have not responded to other tyrosine kinase inhibitors.
Jorge Cortes, MD shares recent...
09/10/2025
Oncology
Andreas Hochhaus, MD
Conference Coverage
Asciminib Demonstrates Superior Tolerability vs Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
06/06/2025
Andreas Hochhaus, MD
Andreas Hochhaus, MD, shares results from the ASC4START trial which found asciminib to be more tolerable than nilotinib among patients with newly diagnosed chronic phase chromic myeloid leukemia.
Andreas Hochhaus, MD, shares results from the ASC4START trial which found asciminib to be more tolerable than nilotinib among patients with newly diagnosed chronic phase chromic myeloid leukemia.
Andreas Hochhaus, MD, shares...
06/06/2025
Oncology
Fadi Haddad, MD
Videos
Latest Strategies for Treating Patients With Chronic Myeloid Leukemia
02/24/2025
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most...
02/24/2025
Oncology
Jorge Cortes, MD
Videos
Asciminib Demonstrates Favorable Safety and Tolerability for Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Compared With Tyrosine Kinase Inhibitor Therapy
01/29/2025
Jorge Cortes, MD
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine...
01/29/2025
Oncology
David Andorsky, MD
Conference Coverage
Asciminib Continues to Demonstrate Efficacy and Tolerability Among Patients With CML in Chronic Phase
01/10/2024
David J. Andorsky
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting, David Andorsky, MD, discussed an interim analysis of the AIM4CML trial, which indicated that asciminib treatment continued to demonstrate efficacy and tolerability among patients with CML chronic phase.
At the 65th ASH Annual Meeting,...
01/10/2024
Oncology
Ehab Atallah, MD
Videos
Management of CML: New Agents and Monitoring for MRD
10/19/2022
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an update on the management of patients with CML, highlighting new available agents and the role of monitoring for MRD.
Ehab Atallah, MD, provides an...
10/19/2022
Oncology
Podcasts
Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
06/04/2021
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares findings from the OPTIC trial on a dosing regimen of ponatinib for patients with CP-CML. These data are being presented at the 2021 ASCO Annual Meeting.
Jorge Cortes, MD, shares...
06/04/2021
Oncology
Interview
Dr Atallah Assesses Outcomes Following the Discontinuation of TKIs in CML
02/16/2021
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Ehab L. Atallah, MD, discusses the findings of a study which looked at outcomes after TKI cessation in patients with CML.
Ehab L. Atallah, MD, discusses...
02/16/2021
Oncology
Podcasts
Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML
12/11/2020
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus discusses the significance of the ASCEMBL trial, and proposes the question of how to eliminate persisting leukemic stem cells (LSCs) in CML.
In this podcast, Dr Hochhaus...
12/11/2020
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use